This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here is Why Growth Investors Should Buy Amedisys (AMED) Now
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos
by Zacks Equity Research
Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos
5 Stocks With Impressive Interest Coverage Ratio to Buy Now
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR
by Zacks Equity Research
Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amedisys (AMED) Down 9.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Trade War Scaring You? Buy 5 DuPont-Tested Quality Stocks
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived the DuPont way.
Here is Why Growth Investors Should Buy Amedisys (AMED) Now
by Zacks Equity Research
Amedisys (AMED) could produce exceptional returns because of its solid growth attributes.
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
by Zacks Equity Research
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
5 Stocks With Upgraded Broker Ratings Worth Betting on Now
by Swayta Shah
Brokers have more understanding of fundamentals of a company, and also about the overall economy. So, following broker advice is a wise decision.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q1
by Zacks Equity Research
At Home Health and Hospice divisions, Amedisys (AMED) witnesses solid year-over-year growth in Medicare and non-Medicare revenues.
Amedisys (AMED) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights include: Raytheon, Otter, Amedysis, Tutor and DMC
by Zacks Equity Research
Zacks.com featured highlights include: Raytheon, Otter, Amedysis, Tutor and DMC
Amedisys (AMED) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Buy These 5 Low Leverage Stocks to Avoid Huge Losses
by Zacks Equity Research
Companies with large debt loads are more vulnerable during economic downturns and can even go bankrupt in the worst-case scenario
These 5 Stocks Boast Impressive Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Amedisys (AMED) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences Takes Over CAS Medical Systems for $100M
by Zacks Equity Research
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) is expected to benefit from the launch of its VITAS Healthcare Inpatient Hospice Unit.
Medidata Launches Acorn Artificial Intelligence Company
by Zacks Equity Research
Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.
Hologic's Diagnostics Grows Strong, Escalating Costs a Woe
by Zacks Equity Research
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
ResMed Launches AirFit P30i Nasal Pillows Mask in the US
by Zacks Equity Research
ResMed (RMD) to expand its portfolio of sleep apnea devices on the back of AirFit P30i nasal pillows mask.
Medtronic's (MDT) Study Shows Positive Results of TDD Use (revised)
by Zacks Equity Research
The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Zacks.com featured expert Kevin Matras highlights: Medifast, Foot Locker, Amedisys, Comfort Systems and CarGurus
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Medifast, Foot Locker, Amedisys, Comfort Systems and CarGurus
Zacks.com featured expert Kevin Matras highlights: WellCare Health Plans, Domtar, Amedysis, Fastenal and DMC Global
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: WellCare Health Plans, Domtar, Amedysis, Fastenal and DMC Global